Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tumors Avoid Destruction by Immune System

By LabMedica International staff writers
Posted on 19 Feb 2018
A molecular and pathway that aids tumors in avoiding destruction by the immune system was found to comprise natural killer cells, conventional type 1 dendritic cells, and prostaglandin E2.

Conventional type 1 dendritic cells (cDC1) are critical to a tumor's ability to avoid destruction by the immune system. More...
In this regard, investigators at The Francis Crick Institute (London, United Kingdom) found that cDC1 accumulation in mouse tumors often depended on natural killer (NK) cells that produced the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, CCL5, XCL1, and XCL2 transcripts within tumors were found to correlate closely with gene signatures of both NK cells and cDC1 and were associated with increased over all patient survival.

In a recent paper published in the February 8, 2018, online edition of the journal Cell, the investigators extended these findings by reporting that tumor-derived prostaglandin E2 (PGE2) impaired NK cell and cDC1 attraction, which resulted in improved ability of the cancer to avoid immune response.

"Our findings have given us a renewed appreciation of the importance of natural killer cells and cDC1 in the immune response against cancer," said senior author Dr. Caetano Reis e Sousa, Senior Group Leader at the Francis Crick Institute. "It is still early days, but attracting more cDC1 to tumors could be the basis of a new immunotherapy for cancer patients. Now that we know a bit better how this key anti-cancer response works, we can look at identifying other ways in which cancers get around it. This understanding will ultimately help us to develop new immunotherapy approaches to help more patients."

Related Links:
The Francis Crick Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic Hematology Analyzer
LABAS F9000
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The advanced test enables early, definitive detection of respiratory infections and pneumonia in critically ill patients (Photo courtesy of Shutterstock)

Rapid Test Detects Early Signs of Pneumonia in Critically Ill Hospitalized Patients

Hospital-acquired infections (HAIs) remain a significant source of life-threatening illness in intensive care, demanding fast and accurate diagnosis to ensure effective treatment. Hospital-acquired pneumonia... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.